Breaking the MM Treatment Burden: Precision Prevention of Infection, Optimization of Administration Routes, and Future Outlook for Trispecific Antibodies 

Breaking the MM Treatment Burden: Precision Prevention of Infection, Optimization of Administration Routes, and Future Outlook for Trispecific Antibodies 

At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has become a major challenge for clinicians. This meeting invited Professor Joseph Mikhael from City of Hope, Professor Maria-Victoria Mateos from the University Hospital of Salamanca, and Professor Xavier Leleu from Poitiers University Hospital to conduct an in-depth discussion on "Managing the Burden of MM Treatments."
Moving from Relapsed/Refractory to Early Treatment: Professor Cyrille Touzeau Interprets the EMN34 Study, Elranatamab Opens a New Chapter in Precision Intervention for HR SMM

Moving from Relapsed/Refractory to Early Treatment: Professor Cyrille Touzeau Interprets the EMN34 Study, Elranatamab Opens a New Chapter in Precision Intervention for HR SMM

In the evolution of treatment for Multiple Myeloma (MM), moving highly effective therapies forward to the early stages of the disease has become a current research hotspot. For patients with High-Risk Smoldering Multiple Myeloma (HR SMM), whether early active intervention can delay or even prevent its transformation into active myeloma is a focus of clinical attention. At a recent international academic conference, Professor Cyrille Touzeau from the University Hospital of Nantes in France shared the preliminary results of the ERASMM (EMN34) study. This study aimed to evaluate the safety and efficacy of the BCMA×CD3 bispecific antibody Elranatamab in patients with HR SMM. This journal has specially compiled the highlights of the conference for our readers.
100% Objective Response Rate! AMC-095 Study Confirms the Efficacy and Safety of Ibrutinib Integrated into R-da-EPOCH for HIV-Associated DLBCL

100% Objective Response Rate! AMC-095 Study Confirms the Efficacy and Safety of Ibrutinib Integrated into R-da-EPOCH for HIV-Associated DLBCL

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Ida Wong-Sefidan (MD) from the AIDS Malignancy Consortium (AMC), on behalf of the research team, shared a milestone study. This study aimed to evaluate the clinical benefits of the Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib in combination with dose-adjusted R-EPOCH (R-da-EPOCH) for the treatment of Human Immunodeficiency Virus-associated Diffuse Large B-cell Lymphoma (HIV-DLBCL). The study results not only confirmed the safety of the regimen but also provided critical data support in terms of efficacy and subgroup survival analysis.
ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

ASCO Voices from China | Zhihui Li: Large Real-World Study Highlights the Value of CAR-T-to-Transplant Consolidation in R/R B-ALL

The treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a major clinical challenge. While CAR-T cell therapy can induce rapid and deep remissions, many patients continue to face a substantial risk of relapse. Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy has emerged as a promising curative strategy. However, evidence regarding its long-term efficacy, optimal timing, and the role of molecular biomarkers in guiding treatment decisions has remained limited.
ASCO Spotlight | Prof. Jun Guo & Prof. Shilpa Gupta: 3.5-Year EV-302 Follow-Up Highlights the Curative Potential of EV + Pembrolizumab in Advanced Urothelial Carcinoma

ASCO Spotlight | Prof. Jun Guo & Prof. Shilpa Gupta: 3.5-Year EV-302 Follow-Up Highlights the Curative Potential of EV + Pembrolizumab in Advanced Urothelial Carcinoma

The 2026 ASCO Annual Meeting has officially opened, bringing a wealth of landmark studies in genitourinary oncology and providing new momentum for precision treatment in urothelial carcinoma (UC). To promote standardized and precision-based management of urologic cancers in China, the Hainan Lecheng Hongyuan Medical Technology Innovation and Development Research Institute launched the “Academic Exchange Program on Precision Diagnosis and Treatment of Urologic Tumors,” bringing together leading experts to interpret the latest advances.
 ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape

 ASCO Voices from China | Professor Xinan Sheng and Professor Cuijian Zhang: First-Line Approval of Toripalimab for Metastatic Urothelial Carcinoma Marks a New Era for China-Developed Therapy and Reshapes the Treatment Landscape

For many years, platinum-based chemotherapy has remained the standard first-line treatment for urothelial carcinoma, yet outcomes have remained suboptimal. As targeted therapies and immunotherapy continue to advance rapidly, there is growing demand for more effective precision treatment strategies.
COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

COMy 2026 | Professor Salomon Manier: Survival Breakthroughs and a New Era of Personalized Treatment for Transplant-Ineligible Multiple Myeloma

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma (MM), the congress brought together leading experts from around the world to discuss the latest advances in research, novel therapies, and patient care.
ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

ESMO BC Voices From China | Professor Nanlin Li: Neratinib-Based Combination Therapy Opens a New Path Forward for T-DXd-Resistant HR+/HER2+ Advanced Breast Cancer

Trastuzumab deruxtecan (T-DXd) has dramatically reshaped the treatment landscape for advanced HER2-positive breast cancer because of its outstanding efficacy. It is now considered the standard second-line treatment for HER2-positive advanced breast cancer and has also demonstrated remarkable activity in both the first-line metastatic and early breast cancer settings.
CSCO BC 10th Anniversary Tribute | Professor Zefei Jiang: A Decade of Progress — CSCO BC Leading China’s Breast Cancer Field Toward a New Global Era

CSCO BC 10th Anniversary Tribute | Professor Zefei Jiang: A Decade of Progress — CSCO BC Leading China’s Breast Cancer Field Toward a New Global Era

Along the long journey of breast cancer prevention and treatment, the successful convening of the 2026 National Breast Cancer Conference stands as a shining milestone. Even more significant is the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC). Over the past decade, CSCO BC has grown from its inception into a major driving force in China’s breast cancer field, achieving remarkable progress in clinical research, guideline development, promotion of standardized care, and international academic collaboration.